A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 23, 2016

Conditions
Lymphoma, B-Cell
Interventions
DRUG

obinutuzumab

1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.

DRUG

cyclophosphamide

750 mg/m\^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.

DRUG

doxorubicin

50 mg/m\^2 IV, Day 1 of each 21-cycle, 6 cycles.

DRUG

prednisone

100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.

DRUG

vincristine

1.4 mg/m\^2 IV, Day 1 of each 21-day cycle, 6 cycles.

Trial Locations (38)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

MSKCC at Sleepy Hollow, Sleepy Hollow

11570

MSKCC at Mercy Med Ctr, Rockville Centre

11725

Memorial Sloan-Kettering; Cancer Center, Commack

24014

Blue Ridge Cancer Care - Roanoke, Roanoke

27262

Emerywood Hematology and Onc, High Point

29425

Medical University of SC (MUSC), Charleston

30060

Northwest Georgia Oncology Centers PC - Marietta, Marietta

33719

Florida Cancer Specialists; Saint Petersburg, St. Petersburg

37203

SCRI-Tennessee Oncology, Nashville

40245

Jewish Cancer Care, Louisville

50010

McFarland Clinic, Ames

54311

Aurora Bay Care Medical Center, Green Bay

59802

MT Cancer Inst Fndtn; MT Can Spec, Missoula

60611

Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago

75702

USO - Tyler Cancer Ctr, Tyler

76177

Onc & Hem Assoc; USO Cent Pharm, Fort Worth

77030

MD Anderson Cancer Center Department of Lymphoma & Myeloma, Houston

Methodist Hospital Research Institute, Houston

78229

Cancer Therapy & Research Center, San Antonio

80045

University of Colorado Cancer Center Department of Hematology, Aurora

80218

Rocky Mountain Cancer Ctr - Denver (Williams), Denver

83814

Kootenai Medical Center, Coeur d'Alene

87401

San Juan Oncology Associates, Farmington

89128

Comprehensive Cancer Centers of Nevada, Las Vegas

92024

cCare, Encinitas

97477

Willamette Valley Cancer Insitute and Research Center, Springfield

98684

Northwest Cancer Specialists - Vancouver, Vancouver

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

99208

Medical Oncology Associates, Spokane

35294-3300

University of Alabama at Birmingham, Birmingham

06856

Norwalk Hospital, Norwalk

33901-8101

Florida Cancer Specialists; Department of Oncology, Fort Myers

61615-7828

Onc Hem Assoc of Central IL, Peoria

01655

University of Massachusetts Medical School, Worcester

48109-0934

University of Michigan, Ann Arbor

07920

MSKCC at Basking Ridge, Basking Ridge

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT01414855 - A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | Biotech Hunter | Biotech Hunter